Figure S1. **Patient flow diagram**

Enrollment

Assessed for eligibility (n=242)

Allocated to vopratelimab + nivolumab (n=131)

* Received intervention (n=131)
* Did not receive intervention (n=0)

Discontinued intervention (n=128)

* Disease progression [106]
* Adverse event [6]
* Investigator decision [3]
* Withdrawal of consent [6]
* Death [2]
* Other [5]

Excluded (n=24)

Discontinued intervention (n=70)

* Disease progression [64]
* Adverse event [2]
* Investigator decision [2]
* Withdrawal of consent [2]
* Death [0]
* Other [0]

Allocated to vopratelimab (n=70)

* Received intervention (n=70)
* Did not receive intervention (n=0)

Allocation

Analysis

Follow-Up

Allocated (n=201)

Safety Set (n=131)

* Excluded (n=0)

Response evaluable set (n=119)

* Excluded (n=12)

Analyzed for PMBC ICOS-hi (n=34)

* Excluded (n=0)

Analyzed for TIS (n=60)

* Excluded (n=0)

Safety Set (n=70)

* Excluded (n=0)

Response evaluable set (n=68)

* Excluded (n=2)

Analyzed for PMBC ICOS-hi (n=10)

* Excluded (n=0)

Analyzed for TIS (n=29)

* Excluded (n=0)